Strengthening Business Competitiveness and Stability

On April 13, Ildong Pharmaceutical held a board meeting and resolved to absorb and merge its new drug research and development subsidiary, Yunovia.


This merger is an absorption-type merger involving a wholly owned subsidiary. It will be conducted as a small-scale merger without capital increase, meaning no new shares will be issued. The merger ratio between Ildong Pharmaceutical and Yunovia is 1 to 0.

Exterior view of Ildong Pharmaceutical Headquarters in Seocho-gu, Seoul. Ildong Pharmaceutical

Exterior view of Ildong Pharmaceutical Headquarters in Seocho-gu, Seoul. Ildong Pharmaceutical

View original image

The record date for determining shareholders is April 30, and the merger date is set for June 16, 2026.


The company stated that the merger decision was made to respond effectively to changes in the business environment and increasing uncertainties, while also strengthening business competitiveness.


The strategy is to ensure operational stability by appropriately addressing current market conditions and institutional factors—such as the implementation of the revised drug pricing system—while streamlining the corporate structure to enhance management efficiency.


In addition, the company aims to internalize R&D assets and achieve focused, integrated management. This will allow Ildong Pharmaceutical to pursue core tasks such as new drug research and development with continuity, while also protecting and increasing shareholder value.


Last year, Ildong Pharmaceutical, through its affiliate Yunovia, successfully derived topline data for the Phase 1 clinical trial of its 'GLP-1RA' obesity treatment (ID110521156). The company also achieved meaningful results in the field of new drug R&D, including advancing its 'P-CAB' peptic ulcer treatment (Fadoprazan) into Phase 3 clinical trials.


Ildong Pharmaceutical plans to use the merger with Yunovia as a springboard to accelerate commercialization efforts—including potential out-licensing—for major pipeline assets such as the GLP-1RA obesity treatment and P-CAB peptic ulcer treatment.



Furthermore, at the group level, the company will reorganize its R&D system and strategy to strengthen its new drug research and development capabilities and business execution, while also establishing an organic collaboration system among related organizations.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing